Yang Lingshuang, Yang Juan, Zhang Tiantian, Xie Xinqiang, Wu Qingping
Modern Industrial College of Traditional Chinese Medicine and Health, Zhejiang Lishui Service Platform for Technological Innovations in Traditional Chinese Medicine Industry, Lishui Institute of Traditional Chinese Medicine, Lishui University, Lishui, Zhejiang, China.
College of Food Science, South China Agricultural University, Guangzhou, Guangdong, China.
Microbiol Spectr. 2025 Aug 5;13(8):e0048224. doi: 10.1128/spectrum.00482-24. Epub 2025 Jul 10.
Atherosclerosis is a common chronic inflammatory cardiovascular disease affecting both coronary and peripheral arteries, which is influenced by multiple factors. It is increasingly evident that gut microbes and their byproducts play a crucial role in the development of atherosclerosis. The most representative feature of microbial dysbiosis in coronary artery disease patients is the reduction of the abundance of the phylum Bacteroidetes and the increase of the abundance of the phylum Firmicutes, which may cause changes in functional genes and metabolites. The gut microbiota and its metabolites influence the early, intermediate, and late stages of atherosclerosis mainly by inhibiting or promoting inflammatory responses. In addition, the reshaping of gut microbiota through probiotics, prebiotics, and fecal microbiota transplantation (FMT) is discussed as an alternative to traditional therapeutic methods. By summarizing how gut microbiota and their metabolites affect the process of atherosclerosis, we can better understand the complex relationship between gut microbiota and atherosclerosis.IMPORTANCEAtherosclerosis is an inflammatory cardiovascular disease, making it crucial to understand its pathogenesis and develop effective treatments. This review thoroughly examines the literature, emphasizing the gut microbiome as a key factor influencing atherosclerosis. It also explores how the gut microbiota and its metabolites impact the primary, intermediate, and advanced stages of atherosclerosis and proposes that remodeling the gut microbiota is a promising strategy for improving atherosclerosis.
动脉粥样硬化是一种常见的慢性炎症性心血管疾病,影响冠状动脉和外周动脉,受多种因素影响。越来越明显的是,肠道微生物及其代谢产物在动脉粥样硬化的发展中起着关键作用。冠心病患者微生物群失调最具代表性的特征是拟杆菌门丰度降低,厚壁菌门丰度增加,这可能导致功能基因和代谢产物的变化。肠道微生物群及其代谢产物主要通过抑制或促进炎症反应影响动脉粥样硬化的早期、中期和晚期。此外,还讨论了通过益生菌、益生元及粪便微生物群移植(FMT)重塑肠道微生物群,作为传统治疗方法的替代方案。通过总结肠道微生物群及其代谢产物如何影响动脉粥样硬化的进程,我们可以更好地理解肠道微生物群与动脉粥样硬化之间的复杂关系。
重要性
动脉粥样硬化是一种炎症性心血管疾病,了解其发病机制并开发有效的治疗方法至关重要。本综述全面审视了相关文献,强调肠道微生物群是影响动脉粥样硬化的关键因素。它还探讨了肠道微生物群及其代谢产物如何影响动脉粥样硬化的初级、中级和高级阶段,并提出重塑肠道微生物群是改善动脉粥样硬化的一种有前景的策略。